Hyperfine Inc (HYPR) News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Hyperfine, Inc. Reports Third Quarter 2024 Financial Results

GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking...

Hyperfine Announces European Launch with CE Approval

CE approval of the latest generation Swoop® system software is a significant milestone in Hyperfine’s...

Hyperfine Announces Alzheimer’s Research with Promising Swoop® System Data and Advanced Image Quality

Today’s presentation at CTAD, a leading international Alzheimer's conference, expands research supporting the...

Hyperfine, Inc. to Announce Third Quarter 2024 Financial Results on November 12, 2024

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable...

Hyperfine Swoop® Portable MR Imaging® System Utilized in Multicenter SAFE MRI ECMO Study Published in the September 29th Issue of Circulation

The SAFE MRI ECMO study evaluated the use of ultra-low-field portable MR imaging on ICU patients undergoing...

Hyperfine Announces Promising Interim Findings on the Value of Portable, Ultra-low-field MR Imaging for Acute Stroke Care

The Swoop® Portable MR Imaging® system shows faster time-to-scan compared to conventional MRI and good specificity in emergency stroke...

Researchers to Monitor Astronaut Brain Health Using Images Acquired with the Hyperfine, Inc. Swoop® Portable MR Imaging® System

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging...

Hyperfine, Inc. to Participate in Upcoming Investor Conferences

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Hyperfine, Inc. Reports Record Quarterly Revenue and Raises FY 2024 Revenue Guidance

─ Reports $3.6M in Q2 2024 Revenue; 50% Gross Margin─ Raises FY 2024 Revenue Guidance to $13-16M GUILFORD...

Hyperfine Announces Presentation of Initial Data from Observational Clinical Studies Evaluating the Use of Portable MR Brain Imaging for Alzheimer's Patients

Two poster presentations at AAIC provide early evidence of the value of ultra-low-field Swoop® system MR brain images in ARIA-E detection and...